Latest Medical Cannabis Sector News

Cann Group Limited (ASX, CAN) launches a $2.5 million Share Purchase Plan offering eligible shareholders discounted shares and attaching options, supporting its recent debt restructure and growth ambitions.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.